A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
The purpose of this study is to measure safety and efficacy of buntanetap capsules compared
with placebo capsules in participants with early PD.
Study details include:
- The study duration will be up to 7-8 months.
- The double-blind treatment duration wil...
Age: 40 - 85 years
Gender: All
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
This open-label study is designed to assess the long-term safety and tolerability of
dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients
that have completed an Addex sponsored double-blind clinical trial of dipraglurant.
Age: 30 - 85 years
Gender: All
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients
with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg
per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be ba...
Age: 30 - 85 years
Gender: All
LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease
Single site observational study focused on elucidating the genes and biochemical pathways
involved in causing Parkinson disease.
Age: 30 years - 66+
Gender: All
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort
The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational,
multi-center natural history study to assess progression of clinical features, digital
outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progre...
Age: 30 years - 66+
Gender: All
PDGeneration: Mapping the Future of Parkinson's Disease
To assess the feasibility, impact, and participant satisfaction of offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care for People with Parkinson's disease (PWP).
Age: 18 years - 66+
Gender: All
A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).
This is a multi-center, randomized, double blind, active controlled clinical Study. Following
a screening period, eligible subjects will be enrolled to an open-label oral IR LD/CD
adjustment period; then an open-label ND0612 conversion period; then after optimizatio...
Age: 30 - 80 years
Gender: All
Nilotinib in Parkinson's Disease
This study will assess the safety and tolerability of daily oral administration of nilotinib
(150-300mg once daily) in Parkinson's Disease.
Age: 40 - 79 years
Gender: All